Topical Aspalathus Linearis Composition for Skin Repigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypopigmentation disorders, such as vitiligo and leukoderma, often cause side effects and primarily focus on reducing melanin production rather than stimulating it, with limited efficacy and safety concerns.
Innovation Solution
A topical composition containing a 100 μg/mL ethanolic extract from the plant Aspalathus linearis, combined with a dermatologically acceptable carrier, stimulates melanin production and transfer, offering a safer alternative for treating hypopigmentation disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (corticosteroids, phototherapy, surgical therapies) are used to treat hypopigmentation disorders, then some level of treatment effect is achieved, but significant side effects occur including skin atrophy, pigmentation alterations, viral infections, and other harmful effects
Solution Approach 1:
The patent employs a plant-based extract (Aspalathus linearis) that can be easily obtained and applied topically, replacing expensive and complex medical treatments. The extract is applied in a simple topical composition that penetrates the skin barrier, providing a safer alternative without the severe side effects of corticosteroids and phototherapy.
Solution Approach 2:
The patent uses a topical composition as an intermediary medium to deliver the active plant extract to the skin. This composition facilitates the transfer of beneficial compounds from the plant to the skin, enabling treatment without direct exposure to harmful conventional therapies.
2Reliability
If current treatments focus on reducing melanin production, then some treatment effect is achieved, but melanin production is not stimulated in areas with pigment loss
Solution Approach 1:
Instead of following the conventional approach of reducing melanin production, the patent inverts the strategy by stimulating melanin production. The Aspalathus linearis extract actively promotes melanogenesis and melanosome transfer, addressing the root cause of hypopigmentation rather than merely suppressing pigment production.
Solution Approach 2:
The patent changes the fundamental parameter of melanin production from suppression to stimulation. By using the plant extract, the treatment shifts the balance toward increased melanin synthesis and transfer, thereby repigmenting affected areas rather than maintaining pigment reduction.
3Reliability
If UV radiation is used for treatment, then pigmentation can be stimulated, but overexposure leads to increased skin aging and development of melanomas and squamous cell cancers
Solution Approach 1:
The patent replaces the physical mechanism of UV radiation with a chemical/biological mechanism using plant extract. Instead of using ultraviolet light to stimulate melanin production, the treatment uses bioactive compounds from Aspalathus linearis that naturally promote melanogenesis and melanosome transfer without the harmful effects of UV exposure.
Solution Approach 2:
The patent converts the harmful UV radiation into a beneficial treatment by using an alternative natural substance. The Aspalathus linearis extract provides the same pigmentation-stimulating effect as UV therapy but without the carcinogenic and aging effects, essentially replacing a harmful mechanism with a beneficial one.
Data Source
AI summary
The present invention relates to a topical composition comprising a 100 μg/mL ethanolic extract from the plant Aspalathus linearis together with a dermatologically acceptable carrier for use in a method of preventing or treating a hypopigmentary disorder of skin in a subject comprising applying the topical composition to the skin of the subject. The invention further relates to methods of preventing or treating a hypopigmentary disorder of skin in a subject comprising applying the topical composition to the skin of the subject.